Erythema multiforme-like papules after COVID vaccine administration

Area of Science:

• Dermatology
• Immunology
• Vaccinology

Background:

• The widespread use of mRNA vaccines like mRNA-1273 (Moderna) for SARS-CoV-2 has prompted investigation into potential adverse cutaneous reactions.
• Understanding vaccine-related dermatological events is crucial for public health and patient safety.

Observation:

• A patient presented with a unique dermatopathology incident following the second dose of the mRNA-1273 vaccine.
• The presentation included transient purpuric interface dermatitis with erythematous papules and erythema multiforme-like features.
• The onset of symptoms was noted 5 days post-vaccination.

Findings:

• The patient developed purpuric interface dermatitis characterized by micro-vesiculation.
• The observed dermatological reaction was transient and resolved completely.
• No long-term sequelae were reported following the resolution of the skin condition.

Implications:

• This case highlights a rare, self-limiting cutaneous side effect associated with the mRNA-1273 SARS-CoV-2 vaccine.
• Further research may be needed to elucidate the immunopathological mechanisms underlying vaccine-induced purpuric interface dermatitis.
• Clinicians should be aware of this potential dermatological manifestation in post-vaccination assessments.